Related Experiment Video
Updated: Jun 7, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer
Jyoti Malhotra1, Edward S Kim1
1City of Hope National Medical Center, Duarte, CA.
Abstract:
Until the early 2000s, advanced or metastatic non-small cell lung cancer (NSCLC) was treated as a single disease with all histologic subtypes treated alike with standard chemotherapy agents. Over the past two decades, the treatment paradigms for advanced NSCLC have changed dramatically with the discovery of multiple targeted therapies that are now approved for the treatment of NSCLC tumors with specific oncogene drivers or molecular alterations. Molecular testing has become integrated and critical for the clinical management of advanced NSCLC. The discovery and success of these targeted therapies have reshaped the classification of NSCLC on the basis of molecular classification and enabled a personalized approach in thoracic oncology. In this review, we discuss recent developments in the molecular profiling of NSCLC, and approved and emerging targeted therapies for the treatment of NSCLC.
Insights
Advanced non-small cell lung cancer (NSCLC) treatment has shifted from chemotherapy to targeted therapies based on molecular profiling. This personalized approach improves outcomes for NSCLC patients with specific oncogene drivers.
Area of Science:
- Oncology
- Molecular Biology
- Thoracic Medicine
Background:
- Advanced non-small cell lung cancer (NSCLC) was historically treated uniformly with chemotherapy.
- Recent decades have seen a paradigm shift in NSCLC management.
- The discovery of oncogene drivers has revolutionized treatment strategies.
Purpose of the Study:
- To review recent advancements in molecular profiling for NSCLC.
- To discuss approved and emerging targeted therapies for NSCLC.
- To highlight the transition to personalized medicine in thoracic oncology.
Main Methods:
- Review of scientific literature on NSCLC molecular profiling.
- Analysis of approved targeted therapies for NSCLC.
- Discussion of emerging therapeutic strategies for NSCLC.
Main Results:
- Molecular testing is now critical for advanced NSCLC clinical management.
- Targeted therapies are approved for NSCLC with specific molecular alterations.
- NSCLC classification is increasingly based on molecular drivers.
Conclusions:
- Personalized medicine, driven by molecular profiling, is transforming advanced NSCLC treatment.
- Targeted therapies offer improved outcomes for NSCLC patients with identified oncogene drivers.
- The future of NSCLC management lies in molecularly guided therapeutic approaches.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...